Dutch biotechnology company Crucell N.V. has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth.

Under the terms of the agreement, Crucell would be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities would take place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed.

Crucell N.V. is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide.